BEATBio LEADERSHIP

Michael Kranda, MBA – Chief Executive Officer – Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital for several years, where he led all aspects of their Life Sciences investment efforts. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development. Mr. Kranda started his biotech career at Immunex Corporation where he served as President, COO and Director and is currently a Director for PTC Therapeutics, Inc. (NASDAQ: PTCT).

Gregory G, Mahairas, Ph.D. – President & Chief Scientific Officer. Dr. Mahairas holds a doctorate in Immunology and an MS degree in Molecular Microbiology and Microbial genetics. Dr. Mahairas has over 19 years of scientific leadership experience and is an expert in scientific management, scale-up, and process development. Dr. Mahairas was Chief Technology Officer of VieVax Corporation and Director of the University of Washington High Throughput Sequencing Center. Teams under the direction of Dr. Mahairas mapped and sequenced the rice, corn and soybean genomes and were major contributors to the Human Genome sequencing project. He has made major scientific contributions in the genomics of human, plants and microbes, and, the pathogenesis of tuberculosis, staphylococcus, and mycoplasma infectious disease.

Sam L. Teichman, MD, FACC, FESC, FACP – Chief Medical Officer. Dr. Teichman has nearly 30 years of global clinical research and drug development leadership experience across broad therapeutic areas with a focus on cardiovascular disease and heart failure. As Senior Vice President of R&D and CMO at Corthera, he led the medical effort to develop serelaxin for the treatment of acute heart failure. Corthera was acquired by Novartis in 2010 and applications for serelaxin registration are currently under review at FDA and EMA. More recently, Dr. Teichman was CMO of Chiasma leading the global development program for oral octreotide culminating in a worldwide license agreement with Roche/Genentech in 2013. In addition, he has worked at Genentech, Glycomed and ARYx Therapeutics and has supported programs as a consultant for Scios/J&J, CryoCor, Biomarin, CIRM and Vivus. He has over 80 published original articles, reviews and abstracts in peer-reviewed journals.

BEATBio BOARD OF DIRECTORS

Michael Kranda – Chief Executive Officer.

Gregory G. Mahairas, Ph.D. – President & Chief Scientific Officer.

Sam Teichman, MD – Chief Medical Officer

Jim Leggett, M.D. (Chairman) – Dr. Leggett is the Medical Director of the Diagnostic Vascular Laboratory at Overlake Internal Medicine Associates, and, Medical Director of the Hope Heart Institute. Dr. Leggett received his MD from the University of Arkansas Medical Sciences Center, and his internal medicine and cardiology training at the University of Washington and University of New Mexico School of Medicine respectively. Dr. Leggett is board certified in internal medicine and cardiovascular medicine, and is an expert in the treatment of cardiovascular disease, and non-invasive and invasive techniques to treat coronary and peripheral artery disease.

Michael Regnier, Ph.D. – Scientific co-founder and Scientific Advisory Board Member. Dr. Regnier is Professor and Vice Chairman of the department of Bioengineering at the University of Washington. Dr. Regnier leads the Heart and Muscle Mechanics laboratory in the Department of Bioengineering and is an expert in cardiac and skeletal muscle physiology, muscle dysfunction with disease and development of gene and cell therapies. He is an established Investigator of the American Heart Association, and an Affiliate Investigator of the Benaroya Research Institute. Dr. Regnier holds a Ph.D. in Biology and Neurobiology from the University of Southern California

Craig Tall – Mr. Tall is the managing director of CET Capital Partners LLC, which provides assistance in mergers and acquisitions, financing strategies and other financial matters. Prior to founding CET Capital Partners, he served as Vice Chairman of Washington Mutual Inc. from1999 to 2004 and before that, beginning in 1985, as Executive Vice President of corporate development for Washington Mutual. Earlier in his career he was President and owner of an employee benefits consulting firm. He presently holds board positions for a diverse group of companies, including The Space Needle Corporation, True Blue Inc. (NYSE), Cascadia Capital and Vittana (a not-for-profit global micro student lender). Craig holds a B.S. in Economics from the University of Pennsylvania’s Wharton School.

Chad Waite (Observer for the WFund) – Mr. Waite joined OVP Venture Partners in 1987 and focuses on investments in the digital biology, and network security sectors. His investments include 4thPass, Accelerator, Adapx, Cardima, CellPro, Complete Genomics, Corixa, Filenet, GenoLogics, Limerick BioPharma, NanoString, Quantum Medical, Raytel Medical, Rosetta Inpharmatics, and Seattle Genetics. He currently serves on the Board of Directors of Accelerator, Adapx, Aggregate Knowledge, NanoString (NSTG), Symform, Talyst, The W Fund and Verdezyne. Prior to joining OVP, Chad was a General Partner at Hambrecht & Quist Venture Partners where he focused on investments in IT and life sciences. Chad received his BA in History from Kenyon College and his MBA from Harvard Business School. He is a Trustee at Kenyon College and has also served as a board member of the NVCA.

BEATBio FOUNDERS

Charles E. Murry, M.D., Ph.D. – Scientific co-founder and Chairman of the Scientific Advisory Board. Dr. Murry is Professor of Pathology, Bioengineering and Medicine/Cardiology and Director of the Center for Cardiovascular Biology at the University of Washington. Dr. Murry is one of the foremost experts in cardiac repair, cardiac stem cells and tissue regeneration.

Buddy Ratner, Ph.D. – Scientific co-founder and Scientific Advisory Board member. Professor of Bioengineering and Chemical engineering, and, Director of the University of Washington Engineered Biomaterials. Dr. Ratner is a National Academy of Engineering member and is one of the most highly regarded experts in the area of bioengineering and biomaterials.

Michael Laflamme, M.D., Ph.D. – Scientific co-founder and Scientific Advisory Board member. Associate Professor of Pathology, University of Washington Center for Cardiovascular Biology. Dr. Laflamme is a leader in the field of cardiac physiology, stem cell-derived cardiac tissues and cardiac pacemaker cells.

Michael Regnier, Ph.D. – See board resume section

BEATBio ADVISORS

Barrie Carter, Ph.D. – Dr. Carter was the Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation from 1992 until 2008. Previously, he was at the National Institutes of Health (NIH) for 22 years serving as Chief of the Laboratory of Molecular and Cellular Biology in the National Institute for Diabetes and Digestive and Kidney Diseases from 1982 to 1992. He received his B.Sc. with Honors from the University of Otago, Dunedin, New Zealand and his Ph.D. in the Biochemistry Department of the University of Otago Medical School. Dr. Carter’s long-term research interests are in the molecular biology of viruses, development of AAV vectors and gene therapy. Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology from 1995-2000. Dr. Carter currently serves as a member of the Advisory Committee to the Director of NIH and is a member of the Board of Directors of the American Society for Gene Therapy.

Jane Lebkowski Ph.D. – Dr Lebkowski was recently the Chief Scientific Officer of Geron Corporation. Prior to Geron she was Vice president of Discovery Research at Rhone-Poulenc Rorer and Vice President of R&D at Applied Immune Sciences. Dr. Lebkowski holds a Ph.D. in Biochemistry from Princeton University and is an internationally recognized expert in stem cell biology and regenerative medicine. She has authored over 70 peer – reviewed papers and 12 issued US Patents.

Mark Reisman MD – Dr. Reisman is the Director of Swedish Medical Center Cardiac catheterization laboratory, Partner with Seattle Heart and Vascular Consultants, and, President of the Seattle Science Foundation. He is a Professor of Medicine at the University of Washington and co-chair of the Clinical Outcomes Assessment Program of the State of Washington. Dr. Reisman is board certified in cardiology and has been Principal Investigator for dozens of clinical trials. Dr. Reisman holds a Bachelors Degree from SUNY – Stonybrook, and a Medical Degree from the Sackler Medical School, New York, NY. He did an internship in Internal Medicine at the Robert Wood Johnson Medical Center in Brunswick NJ, a Fellowship in Cardiology at St. Lukes Medical Center in New York, NY, and, a Fellowship in Interventional Cardiology at UC San Diego Medical Center.

Warren Sherman, MD – Dr. Sherman is an Interventional Cardiologist at Columbia University Medical Center/NewYork-Presbyterian Hospital, the Director, Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy, and Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Sherman’s areas of expertise include a cell-based and other regenerative therapies for treating patients with chronic heart failure and following acute myocardial infarction. Dr. Sherman received his B.S. degree from the Massachusetts Institute of Technology, Doctor of Medicine from Upstate University of New York in Syracuse, NY and Cardiology Fellowship at Oregon Health Sciences University

Max Lyon, MBA – Mr. Lyon is a senior executive, entrepreneur, and consultant with a 25 year career in biomedical technology including pharmaceuticals, medical devices/diagnostics and healthcare IT. Major activity has been with startup and development stage companies. Mr. Lyon has been CEO/President of eight medical technology companies, four of which he co-founded, including BioControl Systems, Bainbridge Sciences (Bard Diagnostics), CG Therapeutics, Adeona Pharmaceuticals (AMEX:AEN), NexCura, Confirma, LifeSpex and FiatLux Imaging. Mr. Lyon currently has a consulting practice focused on start-up and development stage companies. In 2005, he received the Frost & Sullivan Northwest Healthcare Entrepreneur of the Year award. He holds both BA (Cornell University) and MBA degrees.